The market performance of Basel Medical Group Ltd has been somewhat unstable.
52-week price history of BMGL Stock
Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Basel Medical Group Ltd’s current trading price is -76.06% away from its 52-week high, while its distance from the 52-week low is 146.76%. The stock’s price range for this period has remained between $0.91 and $9.40. The Healthcare sector company’s shares managed to surpass a trading volume of around 2.1 million for the day, which was noticeably lower compared to the shares’ average daily volume of 7.2 million over the last three months.
Financial Performance and Market Capitalization
Basel Medical Group Ltd (BMGL) has experienced a quarterly decline of -52.53% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 42.28M and boasts a workforce of 32 employees.
Moving average and trading volume data
BMGL Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BMGL stands at 0.67. Similarly, the long-term debt-to-equity ratio is also 0.00.
BMGL Stock Stochastic Average
As of today, the raw stochastic average of Basel Medical Group Ltd over the past 50 days is 15.78%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 21.70%. Additionally, the Stochastic %K and %D values for the company were 42.13% and 35.77%, respectively, over the past 20 days.
BMGL Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data.
